Cargando…
A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women
BACKGROUND AND OBJECTIVE: Relugolix is a gonadotropin-releasing hormone receptor antagonist. Relugolix 40-mg monotherapy is associated with vasomotor symptoms and long-term bone mineral density loss due to hypoestrogenism. This study assessed whether the addition of estradiol (E2) 1 mg and norethind...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386916/ https://www.ncbi.nlm.nih.gov/pubmed/37365436 http://dx.doi.org/10.1007/s40262-023-01269-9 |